# An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

> **NCT01853826** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 481 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT01853826
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-17
- **Primary completion:** 2024-03-06
- **Final completion:** 2024-03-06
- **Target enrollment:** 481 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853826, "An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01853826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*